Locations
San Diego, CA, USA
industry
Biotechnology · DeepTech · Health
Size
51-200 employees
Stage
Series B
founded in
2018
Plexium is a leading next-generation targeted protein degradation (TPD) company that specializes in the rational design and discovery of Monovalent Direct Degraders and Molecular Glues. Utilizing a proprietary ultra-high throughput cell-based screening technology, Plexium is at the forefront of creating innovative therapeutics aimed at addressing significant unmet medical needs, particularly in oncology and neurological conditions. Their differentiated platform allows for a robust and diverse portfolio of targeted protein degrader therapeutics, positioning them strongly in the biotechnology market with a commitment to delivering transformative precision medicines to patients.
Something looks off?On-site & Remote